血流导向装置治疗颅内动脉瘤:不断变化的治疗格局
本文综述血流导向装置治疗颅内动脉瘤的现状,指出该技术应用速度远超临床证据积累,多数为超说明书使用,学习曲线尚处早期。研究最多的Pipeline Embolization Device正转向Pipeline Flex但结局数据稀疏或异质,现有证据支持多数适应证使用单一腔内装置,但分叉部、破裂或解剖复杂动脉瘤的装置选择无法基于当前证据做出推荐。
要点
- 血流导向装置应用速度超过临床证据积累,多数为超说明书使用,学习曲线尚处早期。
- 现有最佳证据支持多数适应证使用单一腔内装置,但需结合经验与相对风险个案决策。
- 分叉部、破裂或解剖复杂动脉瘤的装置选择无法基于当前证据做出推荐。
核心结论
- 现有最佳证据支持多数适应证使用单一腔内装置。
- 分叉部或破裂动脉瘤或解剖复杂病变的装置适用性与选择无法基于当前证据做出推荐。
- 血流导向治疗的适用性必须结合经验及相对于标准治疗或观察的相对风险个案决定。
- 血流导向支架的长期结局数据太有限,不足以可靠地指导临床决策。
研究设计与样本
- 综述,总结血流导向装置的技术规格与关键结局数据,未报告检索范围与纳入文献数量。
诊断标准与关键数值
- 研究最多的为Pipeline Embolization Device,已过渡至Pipeline Flex,但后者结局数据稀疏或异质。
- 替代腔内装置迄今似乎未优于Pipeline Embolization Device,但多缺乏前瞻性研究与长期数据,研究间比较须谨慎。
- 名义技术规格可能与原位性能无关,强调正确影像 sizing 与装置放置的重要性。
- 专为分叉部动脉瘤设计的装置缺乏长期结局数据或近期才可用于临床。
临床应用与阅片要点
- 原文未据此给出推荐。
局限性
- 血流导向技术的临床应用速度远超临床证据的可得性。
- 多数当前使用为超说明书使用,且鉴于在研装置数量,腔内治疗界的学习曲线更接近起点而非终点。
- Pipeline Flex的结局数据稀疏或异质。
- 替代腔内装置多缺乏前瞻性研究与长期数据,研究间比较须谨慎对待。
- 专为分叉部动脉瘤设计的装置缺乏长期结局数据或近期才可用于临床。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Uptake of flow-diverting technology is rapidly outpacing the availability of clinical evidence. Most current usage is off-label, and the endovascular community is nearer the beginning than the end of the learning curve, given the number of devices in development. A comprehensive overview of technical specifications alongside key outcome data is essential both for clinical decision-making and to direct further investigations. Most-studied has been the Pipeline Embolization Device, which has undergone a transition to the Pipeline Flex for which outcome data are sparse or heterogeneous. Alternative endoluminal devices do not appear to be outperforming the Pipeline Embolization Device to date, though prospective studies and long-term data mostly are lacking, and between-study comparisons must be treated with caution. Nominal technical specifications may be unrelated to in situ performance, emphasizing the importance of correct radiologic sizing and device placement. Devices designed specifically for bifurcation aneurysms also lack long-term outcome data or have only recently become available for clinical use. There are no major studies directly comparing a flow-diverting device with standard coiling or microsurgical clipping. Data on flow-diverting stents are too limited in terms of long-term outcomes to reliably inform clinical decision-making. The best available evidence supports using a single endoluminal device for most indications. Recommendations on the suitability and choice of a device for bifurcation or ruptured aneurysms or for anatomically complex lesions cannot be made on the basis of current evidence. The appropriateness of flow-diverting treatment must be decided on a case-by-case basis, considering experience and the relative risks against standard approaches or observation.
引用
- Dmytriw AA, Phan K, Moore JM, et al. On Flow Diversion: The Changing Landscape of Intracerebral Aneurysm Management. AJNR Am J Neuroradiol. 2019. PMID: 30894358. doi:10.3174/ajnr.A6006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。